Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Multicenter Study of Antimicrobial Susceptibility of Anaerobic Bacteria in Korea in 2012

  • Lee, Yangsoon (Department of Laboratory Medicine, Hanyang University College of Medicine) ;
  • Park, Yeon-Joon (Department of Laboratory Medicine, School of Medicine, the Catholic University of Korea) ;
  • Kim, Mi-Na (Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Uh, Young (Department of Laboratory Medicine, Yonsei University Wonju College of Medicine) ;
  • Kim, Myung Sook (Department of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of Medicine) ;
  • Lee, Kyungwon (Department of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of Medicine)
  • Received : 2015.01.06
  • Accepted : 2015.05.11
  • Published : 2015.09.01
⟨ Previous Next ⟩

Abstract

Background: Periodic monitoring of regional or institutional resistance trends of clinically important anaerobic bacteria is recommended, because the resistance of anaerobic pathogens to antimicrobial drugs and inappropriate therapy are associated with poor clinical outcomes. There has been no multicenter study of clinical anaerobic isolates in Korea. We aimed to determine the antimicrobial resistance patterns of clinically important anaerobes at multiple centers in Korea. Methods: A total of 268 non-duplicated clinical isolates of anaerobic bacteria were collected from four large medical centers in Korea in 2012. Antimicrobial susceptibility was tested by the agar dilution method according to the CLSI guidelines. The following antimicrobials were tested: piperacillin, piperacillin-tazobactam, cefoxitin, cefotetan, imipenem, meropenem, clindamycin, moxifloxacin, chloramphenicol, metronidazole, and tigecycline. Results: Organisms of the Bacteroides fragilis group were highly susceptible to piperacillin-tazobactam, imipenem, and meropenem, as their resistance rates to these three antimicrobials were lower than 6%. For B. fragilis group isolates and anaerobic gram-positive cocci, the resistance rates to moxifloxacin were 12-25% and 11-13%, respectively. Among B. fragilis group organisms, the resistance rates to tigecycline were 16-17%. Two isolates of Finegoldia magna were non-susceptible to chloramphenicol (minimum inhibitory concentrations of 16-32 mg/L). Resistance patterns were different among the different hospitals. Conclusions: Piperacillin-tazobactam, cefoxitin, and carbapemems are highly active ${\beta}$-lactam agents against most of the anaerobes. The resistance rates to moxifloxacin and tigecycline are slightly higher than those in the previous study.

Keywords

Acknowledgement

Supported by : Yonsei University College of Medicine

References

  1. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; Approved standard, 8th ed. M11-A8. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
  2. Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013;26:526-46. https://doi.org/10.1128/CMR.00086-12
  3. Pumbwe L, Chang A, Smith RL, Wexler HM. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates. J Antimicrob Chemother 2006;58:543-8. https://doi.org/10.1093/jac/dkl278
  4. Goldstein EJ, Solomkin JS, Citron DM, Alder JD. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis 2011;53:1074-80. https://doi.org/10.1093/cid/cir664
  5. Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin Infect Dis 2007;44:895-900. https://doi.org/10.1086/512197
  6. Lee K, Shin HB, Chong Y. Antimicrobial resistance patterns of Bacteroides fragilis group organisms in Korea. Yonsei Med J 1998;39:578-86. https://doi.org/10.3349/ymj.1998.39.6.578
  7. Yim J, Lee Y, Kim M, Seo YH, Kim WH, Yong D, et al. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital. Ann Lab Med 2015;35:94-8. https://doi.org/10.3343/alm.2015.35.1.94
  8. Jousimies-Somer HR, Summanen P, et al. eds. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Belmont, CA: Star Publishing Co., 2002:55-70.
  9. The US Food and Drug Administration. FDA Approved Drug Products Label for Tygacil, NDA no. 021821 (approved on May 23, 2013). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-821_Tygacil.cfm.
  10. Roh KH, Kim S, Kim CK, Yum JH, Kim MS, Yong D, et al. New cfiA variant and novel insertion sequence elements in carbapenem-resistant Bacteroides fragilis isolates from Korea. Diagn Microbiol Infect Dis 2010;66:343-8. https://doi.org/10.1016/j.diagmicrobio.2009.11.003
  11. Citron DM and Hecht DW. Susceptibility test methods: anaerobic bacteria. In: Versalovic J, Carroll KC, Funke G, et al., eds. Manual of clinical microbiology. 10th ed. Washington, DC: ASM Press, 2011:1204-14.
  12. Koeth LM, Good CE, Appelbaum PC, Goldstein EJ, Rodloff AC, Claros M, et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 2004;53:1039-44. https://doi.org/10.1093/jac/dkh248
  13. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-55. https://doi.org/10.1128/AAC.01435-06
  14. Lee Y, Park Y, Kim MS, Yong D, Jeong SH, Lee K, et al. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. Antimicrob Agents Chemother 2010;54:3993-7. https://doi.org/10.1128/AAC.00481-10
  15. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010;50(S1):S26-33. https://doi.org/10.1086/647940
  16. Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother 2012;56:1247-52. https://doi.org/10.1128/AAC.05823-11
  17. Katsandri A, Avlamis A, Pantazatou A, Petrikkos GL, Legakis NJ, Papaparaskevas J, et al. In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains. Diagn Microbiol Infect Dis 2006;55:231-6. https://doi.org/10.1016/j.diagmicrobio.2006.01.022
  18. Wybo I, Pierard D, Verschraegen I, Reynders M, Vandoorslaer K, Claeys G, et al. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007;59:132-9.
  19. Jacobus NV, McDermott LA, Ruthazer R, Snydman DR. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004;48:1034-6. https://doi.org/10.1128/AAC.48.3.1034-1036.2004
  20. Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007;45:2819-28. https://doi.org/10.1128/JCM.00551-07
  21. Papaparaskevas J, Pantazatou A, Katsandri A, Houhoula DP, Legakis NJ, Tsakris A, et al. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother 2008;62:137-41. https://doi.org/10.1093/jac/dkn134
  22. Soki J, Edwards R, Hedberg M, Fang H, Nagy E, Nord CE, et al. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey. Int J Antimicrob Agents 2006;28:497-502. https://doi.org/10.1016/j.ijantimicag.2006.07.021

Cited by

  1. The Importance of the Early and Appropriate Treatment of Anaerobic Bacteremia Patients vol.48, pp.2, 2015, https://doi.org/10.3947/ic.2016.48.2.143
  2. Virulence arsenal of the most pathogenic species among the Gram-positive anaerobic cocci, Finegoldia magna vol.42, pp.None, 2015, https://doi.org/10.1016/j.anaerobe.2016.10.007
  3. The efficacy of combined therapy with metronidazole and broad-spectrum antibiotics on postoperative outcomes for pediatric patients with perforated appendicitis vol.96, pp.47, 2017, https://doi.org/10.1097/md.0000000000008849
  4. Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms vol.73, pp.2, 2015, https://doi.org/10.1093/jac/dkx351
  5. Anaerobic resistance : should we be worried? vol.32, pp.6, 2015, https://doi.org/10.1097/qco.0000000000000595
  6. Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species vol.39, pp.2, 2015, https://doi.org/10.3343/alm.2019.39.2.190
  7. Antimicrobial Resistance Profile and Nim Gene Detection among Bacteroides fragilis Group Isolates in a University Hospital in South India vol.11, pp.2, 2015, https://doi.org/10.4103/jgid.jgid_116_18
  8. Surveillance of antimicrobial resistance in recent clinical isolates of Gram-negative anaerobic bacteria in a Greek University Hospital vol.62, pp.None, 2015, https://doi.org/10.1016/j.anaerobe.2020.102173
  9. Epidemiology and microbiological features of anaerobic bacteremia in two French University hospitals vol.64, pp.None, 2015, https://doi.org/10.1016/j.anaerobe.2020.102207
  10. Molecular basis of macrolide-lincosamide-streptogramin (MLS) resistance in Finegoldia magna clinical isolates vol.64, pp.None, 2015, https://doi.org/10.1016/j.anaerobe.2020.102220
  11. Antimicrobial Susceptibility Patterns and Wild-Type MIC Distributions of Anaerobic Bacteria at a German University Hospital: A Five-Year Retrospective Study (2015–2019) vol.9, pp.11, 2020, https://doi.org/10.3390/antibiotics9110823
  12. Phenotypic and genotypic antimicrobial resistance in clinical anaerobic isolates from India vol.3, pp.2, 2015, https://doi.org/10.1093/jacamr/dlab044